In A Nutshell A natural compound in grapes, resveratrol, can bind to key ovarian cancer proteins in computer models. Lab studies suggest it may slow tumor growth, reduce inflammation, and boost ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...

Myriad Genetics received approval for a diagnostic test aimed at identifying advanced ovarian cancer patients eligible for treatment with Zejula from the Food and Drug Administration.

BALTIMORE. (KFSN) -- This year alone, 21,000 women will be diagnosed with ovarian cancer. Of those, 14,000 will die. Because the symptoms are so subtle, most women aren't diagnosed until they are in ...

Fuzuloparib monotherapy significantly improved PFS in advanced ovarian cancer, but adding apatinib did not enhance outcomes. The study included patients with newly diagnosed ovarian, fallopian tube, ...

Recent findings published in Scientific Reports highlight a promising target for ovarian cancer drug development, emphasizing the importance of Claudin-4 in tumor progression and resistance. The study ...

December 23, 2008 — In the treatment of advanced ovarian cancer, neoadjuvant chemotherapy before surgical debulking may be the new standard of care — especially in countries where the scheduling of a ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Research, headed by teams at Trinity College Dublin and University College Dublin, has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body’s ...

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial ...

Here I am, nine years later.’ After being diagnosed with advanced ovarian cancer at 39, Caitlin Delaney is advocating for early detection — and giving other women hope.

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...